CSL Ltd. (CSL.AX) Friday said Health Canada has approved Andembry for the treatment of hereditary angioedema (HAE) in patients aged 12 years and older.
HAE is a genetic disorder characterized by recurrent and unpredictable attacks of angioedema.
Health Canada authorization is based on data from the Phase 3 VANGUARD study, in which Andembry reduced HAE attacks by a median of more than 99 percent compared to placebo.
Andembry is already approved in several countries, including the U.S, Australia, the United Kingdom, the European Union, Switzerland, and Japan.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.